Analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of Galmed Pharmaceuticals stock opened at $0.39 on Thursday. The business’s fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.38. The company has a market capitalization of $1.95 million, a P/E ratio of -0.12 and a beta of 0.87. Galmed Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $7.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- What Are Dividend Achievers? An Introduction
- AMD is Down 35%. Now is the Time to Buy the Dip
- 3 Best Fintech Stocks for a Portfolio Boost
- Amazon Stands Tall: New Highs Are in Sight
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
